Advertisement

Ginkgo biloba, inflammation and lipoprotein(a)

  • Giuseppe Lippi
    Correspondence
    Corresponding author at: Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degli Studi di Verona, Ospedale Policlinico G.B. Rossi, Piazzale Scuro 10, 37134 Verona, Italy. Tel.: +39 045 8124516; fax: +39 045 8201889.
    Affiliations
    Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degli Studi di Verona, Verona, Italy
    Search for articles by this author
  • Giovanni Targher
    Affiliations
    Sezione di Endocrinologia e Malattie del Metabolismo, Dipartimento di Scienze Biomediche e Chirurgiche, Università degli Studi di Verona, Italy
    Search for articles by this author
  • Gian Cesare Guidi
    Affiliations
    Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degli Studi di Verona, Verona, Italy
    Search for articles by this author
      We have read with interest the recent article of Rodriguez et al. on the inhibitory effect of Ginkgo biloba on atherosclerosis, which has also been attributed to an attenuation of the risk factors oxidized LDL/LDL and the highly atherogenic lipoprotein(a) (Lp(a)) [
      • Rodriguez M.
      • Ringstad L.
      • Schafer P.
      • Just S.
      • Hofer H.W.
      • Malmsten M.
      • et al.
      Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients.
      ]. We were particularly surprised by the substantial decay of Lp(a) (23.4 ± 7.9%), which actually represents a clinically remarkable outcome since no alternative therapeutical approach has been identified so far for lowering efficiently and safely the plasma concentration of this intriguing lipoprotein [
      • Lippi G.
      • Guidi G.
      Lipoprotein(a): an emerging cardiovascular risk factor.
      ]. However, no reliable explanation has been provided to explain this unpredicted finding.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rodriguez M.
        • Ringstad L.
        • Schafer P.
        • Just S.
        • Hofer H.W.
        • Malmsten M.
        • et al.
        Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients.
        Atherosclerosis. 2007; 192: 438-444
        • Lippi G.
        • Guidi G.
        Lipoprotein(a): an emerging cardiovascular risk factor.
        Crit Rev Clin Lab Sci. 2003; 40: 1-42
        • Gertz H.J.
        • Kiefer M.
        Review about Ginkgo biloba special extract EGb 761 (Ginkgo).
        Curr Pharm Des. 2004; 10: 261-264
        • Yoshikawa T.
        • Naito Y.
        • Kondo M.
        Ginkgo biloba leaf extract: review of biological actions and clinical applications.
        Antioxid Redox Signal. 1999; 1: 469-480
        • Abdel-Salam O.M.
        • Baiuomy A.R.
        • El-batran S.
        • Arbid M.S.
        Evaluation of the anti-inflammatory, anti-nociceptive and gastric effects of Ginkgo biloba in the rat.
        Pharmacol Res. 2004; 49: 133-142
        • Han Y.
        Ginkgo terpene component has an anti-inflammatory effect on Candida albicans-caused arthritic inflammation.
        Int Immunopharmacol. 2005; 5: 1049-1056
        • Lim H.
        • Son K.H.
        • Chang H.W.
        • Kang S.S.
        • Kim H.P.
        Inhibition of chronic skin inflammation by topical anti-inflammatory flavonoid preparation, Ato Formula.
        Arch Pharm Res. 2006; 29: 503-507
        • Lim H.
        • Son K.H.
        • Chang H.W.
        • Kang S.S.
        • Kim H.P.
        Effects of anti-inflammatory biflavonoid, ginkgetin, on chronic skin inflammation.
        Biol Pharm Bull. 2006; 29: 1046-1049
        • Park Y.M.
        • Won J.H.
        • Yun K.J.
        • et al.
        Preventive effect of Ginkgo biloba extract (GBB) on the lipopolysaccharide-induced expressions of inducible nitric oxide synthase and cyclooxygenase-2 via suppression of nuclear factor-kappaB in RAW 264.7 cells.
        Biol Pharm Bull. 2006; 29: 985-990
        • He M.
        • Zhang X.M.
        • Yuan H.Q.
        Clinical study on treatment of pulmonary interstitial fibrosis with ginkgo extract.
        Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005; 25: 222-224
        • Maeda S.
        • Abe A.
        • Seishima M.
        • et al.
        Transient changes of serum lipoprotein(a) as an acute phase protein.
        Atherosclerosis. 1989; 78: 145-150
        • Lippi G.
        • Braga V.
        • Adami S.
        • Guidi G.
        Modification of serum apolipoprotein A–I, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response.
        Clin Chim Acta. 1998; 271: 79-87
        • Ramharack R.
        • Barkalow D.
        • Spahr M.A.
        Dominant negative effect of TGF-beta1 and TNFalpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures.
        Arterioscler Thromb Vasc Biol. 1998; 18: 984-990
        • Solfrizzi V.
        • Panza F.
        • D’Introno A.
        • et al.
        Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease.
        J Neurol Neurosurg Psychiatr. 2002; 72: 732-736
        • Irizarry M.C.
        Biomarkers of Alzheimer disease in plasma.
        NeuroRx. 2004; 1: 226-234
        • Panza F.
        • Solfrizzi V.
        • Colacicco A.M.
        • et al.
        Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline.
        Aging Clin Exp Res. 2006; 18: 144-148